Introduction {#S1}
============

Parkinson's disease (PD) is a common neurological disorder affecting approximately one in 100 adults over age 65. While its root cause stemming from death of dopaminergic neurons in the *substantia nigra* is well-established, the functionally disruptive impact of PD on muscle function is poorly understood. In addition to its roles in locomotion and gait, skeletal muscle is an active participant in tissue cross-talk via secretion of signaling factors produced in muscle tissue (e.g., myokines), which may impact neural function and health ([@B7]; [@B51]). Fittingly, muscular loading through exercise training has received attention as a neuroprotective ([@B1]) or even neurorestorative ([@B3]) therapy, with wide-ranging benefits for neuromuscular function and cognitive health in PD ([@B12]; [@B44]; [@B72]).

Our laboratory has demonstrated that 16 weeks of high-intensity resistance exercise rehabilitation training (RT) not only restores skeletal muscle mass and strength to levels found in healthy adults but also leads to improvements in cognition, well-being, and both overall and motor-specific domains of the Unified Parkinson's Disease Rating Score (UPDRS) and 39-item Parkinson's Disease Questionnaire (PDQ-39), validated metrics of PD severity ([@B24]). Furthermore, fMRI analysis performed immediately after a single acute bout of this RT regimen demonstrates heightened activity in key brain regions, including the *substantia nigra* and prefrontal cortex ([@B27]). If these acute effects are predictive of motor and cognitive adaptations to training ([@B73]) this may provide a mechanistic link to improvements in both motor and non-motor symptoms of PD seen following 16-week RT. It is likely that exercise training elicits an integrated physiological response that leads to these improvements and that key insight may be gained by examining skeletal muscle, which may play a communicative role in these beneficial adaptations.

Our laboratory has also previously shown that coordinated motor unit activation in individuals with PD markedly improves following RT, indicating reduced difficulty performing a functional sit-to-stand task ([@B24]). This improvement is believed to be a reflection of an RT-induced reduction in average motor unit size, which has previously been shown to increase with aging ([@B26]; [@B57]) and specifically PD ([@B6]; [@B25]; [@B33]). The histological manifestation of motor unit remodeling in the *vastus lateralis* is type I myofiber grouping, a skeletal muscle phenotype noticeable in aged adults ([@B69]; [@B55]) but further exaggerated in individuals with PD ([@B25]). Notably, 16-week RT partially reduces the degree of type I grouping in a manner consistent with improvements in motor unit activation and PD-specific indices of disease progression. Thus, along with modulating the severity of other symptoms, exercise-induced demands placed on skeletal muscle partially undo a hallmark pathology in peripheral tissue. We have previously investigated this phenotype extensively ([@B25], [@B26]; [@B33]) demonstrating that muscle communication with the nervous system is concordantly altered. Due to the apparently active role of muscle in signaling to promote survival, reinnervation, and remodeling, maintenance of muscle health through exercise may be of critical importance in PD or older individuals at risk for PD. While exercise dose-response trials are needed to explore the intensity threshold for these effects, our data suggest high-intensity RT has profound effects on motor unit remodeling, likely because all motor units are recruited during near-maximal to maximal contractions (unlike steady-state endurance exercise).

We hypothesized that RT-induced improvements in PD pathology, some of which were fully recovered to healthy levels, would be reflected in the skeletal muscle transcriptome of individuals with PD following RT. To interrogate this, we generated transcriptome-wide skeletal muscle gene expression in a subset of individuals with PD before and after the training regimen detailed in previous work by our laboratory ([@B24]). Data were analyzed using a recently developed bioinformatics framework entitled Pathway-Level Information ExtractoR (PLIER) ([@B42]) to identify molecular programs impacted by 16-week high intensity exercise training in persons with PD and to compare changes in gene expression to healthy old and young comparators. A more comprehensive understanding of the transcriptional profile associated with PD and reversed by exercise aids in illuminating potential mechanisms of neuromuscular remodeling and symptom improvement and identifying potential targets that could be exploited in future interventions leveraging combinatorial therapy.

Materials and Methods {#S2}
=====================

Human Subjects {#S2.SS1}
--------------

Five subjects with idiopathic PD, a subset of 15 participants in our previous RT trial ([@B24]) provided skeletal muscle tissue samples for this study. All persons were Hoehn and Yahr stages 2 (*n* = 3) or 3 (*n* = 2) and medication stable for at least 4 weeks. For an additional exploratory analysis, we included seven additional baseline PD subjects, 12 sex-matched young adults (YA), and 12 age- and sex-matched healthy older adults (OA). Together with the five exercisers, these 36 individuals were previously extensively profiled at baseline in a transcriptome-wide RNA-Seq analysis of type I myofiber grouping ([@B33]). Studies for which the individuals volunteered have been reported previously ([@B31]; [@B45]; [@B24]) and detailed recruitment and eligibility information can be found therein. Both OA and YA were non-exercising, disease-free controls. All volunteers provided written informed consent to have their samples stored and utilized in future studies. Each study was reviewed and approved by the University of Alabama at Birmingham Institutional Review Board and conducted in accordance with the Declaration of Helsinki.

High-Intensity Resistance Rehabilitative Training Intervention and Testing {#S2.SS2}
--------------------------------------------------------------------------

The 16-week RT regimen was performed as previously reported in detail ([@B24], [@B25]). Briefly, sessions (3 days/week) averaged 35--45 min (inter-subject variability due to differences in heart rate response, perceived fatigue, and degree of bradykinesia) and consisted of a combination of strength, power, endurance, balance, and functional training. Between sets of exercises targeting the large muscle groups (three sets of 8--12 repetitions to volitional fatigue for leg press, knee extension, chest press, overhead press, and lat pull down), participants performed functional mobility exercises (e.g., bodyweight squat, push-up, step-up, lunge, side lunge, modified dip for 45--60 s, or a 60 s interval on a treadmill or stationary cycle). Heart rate was maintained above 50% heart rate reserve (HRR) at all times and averaged ≥60% HRR during each session. Throughout the 16-week period, progression was incorporated as previously described ([@B31]; [@B4]). Briefly, resistance loads were increased when a subject completed 12 repetitions for two of three sets at a given resistance while maintaining proper form. Subjects also completed three sets of abdominal crunches each session. Skeletal muscle functional tests were performed as previously outlined in detail in order to assess the maximum load that could be successfully lifted one time (one-repetition maximum, 1RM) and the peak power achieved at a resistance of 45% of 1RM during knee extension exercise ([@B54]; [@B24]). Motor unit activation was assessed during a three-repetition functional sit-to-stand task and is represented as a percentage relative to maximum voluntary contraction measured via surface electromyography, as previously described ([@B54], [@B53]).

Skeletal Muscle Biopsy and Immunohistochemistry {#S2.SS3}
-----------------------------------------------

Skeletal muscle samples were obtained from the vastus lateralis under local anesthesia using a 5 mm Bergstrom biopsy needle with suction and processed to remove excess fat, blood, and connective tissue. Muscle samples to be used for RNA-Seq were snap-frozen in liquid nitrogen (LN~2~) and stored at −80°C until use. A portion of the muscle to be used for immunohistochemistry was mounted in tragacanth gum mixed with Tissue Tek O.C.T. compound (Sakura Finetek, Torrance, CA, United States) atop a square of cork, frozen in isopentane cooled to the temperature of LN~2~, and stored at −80°C.

Myofiber distribution, size, and grouping were determined from 6 μm skeletal muscle sections cut on a cryostat at −20°C, stained with antibodies against the myosin heavy chain I and IIa, imaged on a fluorescence microscope (BX51, Olympus, Tokyo, Japan), and analyzed using ImagePro Premier v9.1, as described in detail previously ([@B26]). All skeletal muscle histological and performance measures were compared between pre- and post-RT using a paired *t*-test or, if non-normally distributed, a Wilcoxon test in R, version 3.4.3 (R Core Team[^1^](#footnote1){ref-type="fn"}).

RNA Isolation and cDNA Library Synthesis {#S2.SS4}
----------------------------------------

Skeletal muscle samples from the five PD subjects pre- and post-RT, along with 7 basal PD, 12 basal OA, and 12 basal YA (total *n* = 41, mean ± SD 7.5 ± 2.1 mg) were homogenized in a Bead Ruptor Elite bead mill homogenizer (Omni International, Kennesaw, GA, United States) at a speed of 4.2 m/s for 2 × 20 s while cooled by liquid nitrogen to 10°C. Muscle homogenates were processed using the Agencourt RNAdvance Tissue Kit (Beckman Coulter, Indianapolis, IN, United States) on a BioMek FX^P^ Laboratory Automation Workstation (Beckman Coulter, Indianapolis, IN, United States). The quality (260/280: 1.9 ± 0.0, 260/230: 1.4 ± 0.1) and integrity (RIN: 8.95 ± 0.05, 28S/18S: 1.6 ± 0.2) of isolated RNA (125 ± 44 ng/μL) were assessed using NanoDrop and an RNA Standard Sensitivity Kit (DNF-471, Advanced Analytical Technologies, Ankeny, IA, United States) on a Fragment Analyzer Automated CE system (Advanced Analytical Technologies). Subsequently, cDNA libraries were constructed from 250 ng of total RNA using the Universal Plus mRNA-Seq kit (NuGEN Technologies, San Carlos, CA, United States). Library concentration (75.8 ± 17.9 ng/μL) was assessed fluorometrically using the Qubit dsDNA HS Kit (Thermo Fisher), and quality (average fragment size: 336 ± 5 bp) was assessed with the Genomic DNA 50Kb Analysis Kit (DNF-467, Advanced Analytical Technologies).

RNA Sequencing and Pre-processing {#S2.SS5}
---------------------------------

Preliminary sequencing of cDNA libraries (average read depth of 90 thousand reads) was performed using a MiSeq system (Illumina, Inc., San Diego, CA, United States) to confirm library quality. Deep sequencing was subsequently performed using an S2 flow cell in a NovaSeq sequencing system (Illumina) (average read depth = 25.5 million pairs of 2 × 50 bp reads). Raw data were processed using bcl2fastq Conversion Software (Illumina) to obtain FASTQ files, and the FASTQ files were aligned to the Human GENCODE hg38 genome using STAR ([@B8]). Gene expression was quantified with featureCounts ([@B39]). The raw FASTQ data and the final gene expression matrix were deposited to GEO (accession number [GSE140089](GSE140089)).

Gene Level Differential Expression Analysis {#S2.SS6}
-------------------------------------------

After filtering for low expression, RNA-Seq data were normalized using a voom correction and compared within the five PD subjects pre- vs. post-RT intervention. Differential expression analysis was performed using Bioconductor ([@B14]) package limma ([@B56]) under R version 3.4.3 (R Core Team^1^). Benjamini--Hochberg correction ([@B5]) for multiple comparisons testing was applied, setting the false discovery rate (FDR) \< 0.05. Using R package biomaRt ([@B66]) transcript Ensembl IDs were converted to gene names, when available, in order to allow for further annotation. Interpretation was limited to genes that exceeded a log2fold-change cutoff of 1 in either direction (i.e., expression doubled or halved following 16-week RT). While use of any stringent cutoff for fold-change is arbitrary, as a meaningful fold-change likely varies based on the biology of a given transcript, the decision to implement this threshold was influenced by our assessment of a large number of dimensions in a small group of individuals. Genes that surpassed the rigorous cutoff of ±1 log2FC were viewed as more robust findings that might hold up in future investigations with larger sample sizes.

Pathway-Level Information ExtractoR {#S2.SS7}
-----------------------------------

In order to identify transcriptional programs that were rescued by RT, a separate, complementary analysis using the PLIER framework ([@B42]) was performed on gene expression data obtained from all 41 skeletal muscle samples (12 basal PD, 5 post-training PD, 12 basal OA, and 12 basal YA). Count data were filtered for expression, retaining 17,786 transcripts, and log~2~ normalization for library size was applied across samples. 5,884 genes were retained in PLIER's deconvolution algorithm. The underlying premise and mathematical approach have been previously described ([@B42]). Briefly, latent variables (LVs) represent eigengene-like patterns in gene expression across samples, where each LV serves as a single measurement to summarize a group of genes that tend to show similar regulatory changes. For each gene in an LV, the degree to which it contributes to the LV is computed as its "loading" (a column of matrix Z, [@B42]). The gene expression of each sample can be approximated by a linear combination of the LVs, and the coefficients of these linear combinations represent the LV "score" of a given sample (a row of matrix B, [@B42]). A key distinction of PLIER is the use of optimized decomposition of the gene expression in each sample into LVs guided by biological pathway gene sets to better capture the biological processes in the data. This is in contrast to a deconvolution method such as principal components analysis (PCA), which generates orthogonal principal components and does not utilize any prior biological knowledge. In contrast to PCA, PLIER LVs are not necessarily orthogonal to each other, and LV scores cannot be obtained by simple projection, but must be computed simultaneously with loadings via PLIER's optimization procedure ([@B42]).

Presently, PLIER identified 25 latent variables (LV), and pathway designations were assigned based on prior knowledge. Each LV was assigned a number for further processing, and further descriptions of identified LVs are available in [Table 4](#T4){ref-type="table"}. For each LV, differences across the four groups were compared using a one-way ANOVA for the three basal groups (Basal OA vs. Basal YA vs. Basal PD) and a paired t-test for the five individuals with PD that underwent RT. Significant difference was declared at *P* \< 0.05. LVs that were different at baseline in PD vs. either healthy group (OA or YA) as well as different between PD pre- to post-RT were investigated further. Within these LVs of interest, the top transcripts associated with the LV were manually annotated. When possible, preferential focus was given to their roles in human skeletal muscle or exercise adaptations; for many genes, data from other tissues or animal models constituted most of the available knowledge base.

Results {#S3}
=======

Subject characteristics are presented in [Table 1](#T1){ref-type="table"}. The impact of the RT intervention has been previously published for a larger cohort (*n* = 15) ([@B24]). For the current subset of five individuals, the RT intervention increased cross-sectional area of IIa fibers (+23%, *P* \< 0.05) and trended strongly toward an expected IIa to IIx/IIax shift in fiber type distribution (IIa: +18%, *P* = 0.08; IIx/IIax: −13%, *P* = 0.06). Furthermore, RT improved the PDQ-39 total score (−8 points, *P* \< 0.05) and led to sizable improvements in whole muscle strength and power (67%, *P* \< 0.05 for each).

###### 

Study subject characteristics.

                                        PD Pre-RT      PD Post-RT    \% or point change
  ------------------------------------- -------------- ------------- --------------------
  **Characteristics at baseline**                                    
   Subjects (*n*)                       5 (4M, 1F)                   
   Age (y)                              67 ± 2                       
   Time since diagnosis (y)             5 ± 2                        
   Hoehn and Yahr stage                 2 (*n* = 3),                 
                                        3 (*n* = 2)                  
   Levodopa equivalency dose            455 ± 181                    
  **Parkinson's disease progression**                                
   MDS-UPDRS total score                53 ± 7         47 ± 5        −6
    Part I: Behavior/mentation/mood     11 ± 4         9 ± 3         −2
    Part II: ADL                        11 ± 3         11 ± 3        0
    Part III: motor                     29 ± 4         27 ± 4        −2
    Part IV: dyskinesia                 2 ± 1          1 ± 1         −1
   PDQ-39 total score                   38 ± 12        30 ± 11       −8\*
    ADL subscore                        21 ± 3         12 ± 4        −9\*
    Mobility subscore                   18 ± 8         17 ± 8        −1
    Emotional well-being subscore       31 ± 8         21 ± 10       −10^†^
    Cognitive impairment subscore       34 ± 9         23 ± 8        −11^†^
  **Myofiber CSA (μm^2^)**                                           
   Type I                               4347 ± 342     5135 ± 399    21 ± 13
   Type IIa                             4532 ± 811     5582 ± 780    30 ± 15
   Type IIx/IIax\*\*                    3762 ± 438     --            --
   Type II total                        3946 ± 514     5582 ± 780    42 ± 12\*
  **Myofiber distribution (%)**                                      
   Type I                               51 ± 4         46 ± 8        5 ± 6
   Type IIa                             34 ± 9         52 ± 8        18 ± 8^†^
   Type IIx/IIax                        15 ± 6         2 ± 1         −13 ± 5^†^
  **Neuromuscular function**                                         
   Knee extension 1RM, kg               77 ± 10        127 ± 14      67 ± 11\*
   Knee extension peak power, W         234 ± 44       364 ± 42      67 ± 18\*
   Motor unit activation (%)            0.68 ± 0.12    0.72 ± 0.16   5 ± 14
  **Type I myofiber grouping**                                       
   Mean group size                      241 ± 151      142 ± 72      −18 ± 62
   Percent of I grouped                 57 ± 15        51 ± 18       −6 ± 17

Values are mean ± SE. PD, Parkinson's disease; RT, 16 weeks of high intensity resistance exercise rehab training; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; PDQ-39, 39-item Parkinson's Disease Questionnaire; ADL, activities of daily living; CSA, cross-sectional area; 1RM, one repetition maximum; W, watts. \*\*Too few IIx/IIax fibers (i.e., ≤25) were present at post-RT time point to obtain a representative myofiber CSA. \*P \< 0.05 vs. pre-RT;

†

P \< 0.10 vs. pre-RT. Data from the full study cohort are presented in a previous publication by our group (

Kelly et al., 2014

).

Genes Differentially Expressed After 16-Week RT in PD Skeletal Muscle {#S3.SS1}
---------------------------------------------------------------------

A total of 706 genes were differentially expressed (FDR \< 0.05) in skeletal muscle of individuals with PD following 16-week RT ([Figure 1](#F1){ref-type="fig"}). Of these, 304 genes were significantly upregulated ([Supplementary Data Sheet 1](#FS1){ref-type="supplementary-material"}). Transcripts meeting or exceeding a fold-change of 2.0 (*n* = 42) are shown in [Table 2](#T2){ref-type="table"}. Predominant biological functions in the upregulated gene set included muscle remodeling, muscle and nerve development, inflammation, and muscle metabolism. An additional 402 genes were downregulated following RT ([Supplementary Data Sheet 2](#FS2){ref-type="supplementary-material"}). Those at or below fold-change of 0.5 (*n* = 31) are shown in [Table 3](#T3){ref-type="table"}. Processes associated with downregulated genes included regulation of skeletal muscle growth, autophagy, and slow muscle metabolism.

![Volcano plot of differentially expressed genes in skeletal muscle of individuals with Parkinson's disease following 16 weeks of high intensity resistance exercise rehabilitation training. A total of 706 genes were significantly different at the 16-week time point vs. pre-training (adjusted *P*-value, or FDR, \<0.05). Of 304 total upregulated genes, 42 met or exceeded a log~2~ fold-change cutoff of 1 (i.e., expression doubled or more following RT). Of 402 total downregulated genes, 29 fell below a log~2~ fold-change cutoff of --1 (i.e., expression halved or less following RT). These gene sets are explored in greater detail in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}.](fphys-11-00653-g001){#F1}

###### 

Skeletal muscle genes upregulated with RT in Parkinson's disease.

  Gene name                                        Description                                                        Fold-change   FDR
  ------------------------------------------------ ------------------------------------------------------------------ ------------- ------
  **Skeletal muscle development and remodeling**                                                                                    
  IGFN1                                            Immunoglobulin-like and fibronectin type III domain containing 1   5.97          0.01
  COL1A1                                           Collagen type I alpha 1 chain                                      3.15          0.02
  COL3A1                                           Collagen type III alpha 1 chain                                    2.85          0.02
  COL4A1                                           Collagen type IV alpha 1 chain                                     2.75          0.02
  PANX1                                            Pannexin 1                                                         2.54          0.02
  CAPN6                                            Calpain 6                                                          2.49          0.02
  PXDN                                             Peroxidasin                                                        2.13          0.01
  AGPAT4                                           1-acylglycerol-3-phosphate *O*-acyltransferase 4                   2.05          0.05
  GJA1                                             Gap junction protein alpha 1                                       2.01          0.02
  **Nervous system development**                                                                                                    
  PCDH17                                           Protocadherin 17                                                   3.51          0.05
  HTR7                                             5-hydroxytryptamine receptor 7                                     3.18          0.03
  ST8SIA2                                          ST8 alpha-*N*-acetyl-neuraminide alpha-2,8-sialyltransferase 2     3.13          0.03
  ADCYAP1R1                                        ADCYAP receptor type I                                             2.32          0.02
  FOXS1                                            forkhead box S1                                                    2.19          0.04
  HECW2                                            HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2    2.19          0.02
  NRP2                                             Neuropilin 2                                                       2.12          0.03
  **Inflammation and immunity**                                                                                                     
  CXCL9                                            C-X-C motif chemokine ligand 9                                     3.47          0.03
  FCN3                                             Ficolin 3                                                          3.07          0.04
  MXRA5                                            Matrix remodeling associated 5                                     2.91          0.03
  COL4A2                                           Collagen type IV alpha 2 chain                                     2.43          0.02
  NOS2                                             Nitric oxide synthase 2                                            2.29          0.05
  FSCN1                                            Fascin actin-bundling protein 1                                    2.20          0.02
  KCNC4                                            Potassium voltage-gated channel subfamily C member 4               2.16          0.04
  LYZ                                              Lysozyme                                                           2.10          0.04
  **Skeletal muscle metabolism**                                                                                                    
  GAL3ST3                                          Galactose-3-*O*-sulfotransferase 3                                 3.17          0.04
  NR5A2                                            Nuclear receptor subfamily 5 group A member 2                      2.91          0.04
  EXOC3L1                                          Exocyst complex component 3 like 1                                 2.90          0.02
  MTFP1                                            Mitochondrial fission process 1                                    2.28          0.02
  SLC7A1                                           Solute carrier family 7 member 1                                   2.16          0.03
  RNF152                                           Ring finger protein 152                                            2.04          0.02
  **PD pathology**                                                                                                                  
  SIPA1L2                                          Signal induced proliferation associated 1 like 2                   4.61          0.01
  LOXHD1                                           Lipoxygenase homology domains 1                                    4.41          0.03
  SCT                                              Secretin                                                           3.47          0.02
  VIPR1                                            Vasoactive intestinal peptide receptor 1                           2.62          0.02
  **Lesser known function**                                                                                                         
  HGC6.3                                           Uncharacterized LOC100128124                                       3.28          0.03
  AC087289.5                                       Novel transcript, antisense to TRIM47                              3.14          0.03
  ITPRIPL1                                         ITPRIP like 1                                                      2.20          0.05
  DSTNP2                                           Destrin, actin depolymerizing factor pseudogene 2                  2.19          0.04
  PITPNM1                                          Phosphatidylinositol transfer protein membrane associated 1        2.16          0.03
  AC015878.1                                       Novel transcript, antisense to GREB1L                              2.13          0.03
  PCAT19                                           Prostate cancer associated transcript 19                           2.01          0.04
  C2CD4C                                           C2 calcium dependent domain containing 4C                          2.00          0.04

Fold-change in gene expression post-RT from pre-RT; FDR, false discovery rate.

###### 

Skeletal muscle genes downregulated with RT in Parkinson's disease.

  Gene name                                         Description                                                            Fold-change   FDR
  ------------------------------------------------- ---------------------------------------------------------------------- ------------- ------
  **Regulation of muscle growth and development**                                                                                        
  GREM2                                             Gremlin 2, DAN family BMP antagonist                                   0.15          0.04
  NPTX1                                             Neuronal pentraxin 1                                                   0.27          0.03
  MSTN                                              Myostatin                                                              0.33          0.02
  ACTN3                                             Actinin alpha 3 (gene/pseudogene)                                      0.36          0.02
  IL32                                              Interleukin 32                                                         0.43          0.02
  LOXL4                                             Lysyl oxidase like 4                                                   0.44          0.02
  RRAD                                              RRAD, Ras related glycolysis inhibitor and calcium channel regulator   0.46          0.02
  TSPAN8                                            Tetraspanin 8                                                          0.48          0.03
  **Autophagy and apoptosis**                                                                                                            
  NME9                                              NME/NM23 family member 9                                               0.35          0.02
  ARG2                                              Arginase 2                                                             0.35          0.04
  GGT7                                              Gamma-glutamyltransferase 7                                            0.43          0.02
  SH3RF2                                            SH3 domain containing ring finger 2                                    0.46          0.03
  **Metabolism**                                                                                                                         
  GDA                                               Guanine deaminase                                                      0.25          0.04
  MYH1                                              Myosin heavy chain 1                                                   0.26          0.04
  CALML6                                            Calmodulin like 6                                                      0.27          0.01
  TRARG1                                            Trafficking regulator of GLUT4 (SLC2A4) 1                              0.33          0.05
  CACNA1E                                           Calcium voltage-gated channel subunit alpha1 E                         0.38          0.05
  PRKAG3                                            Protein kinase AMP-activated non-catalytic subunit gamma 3             0.44          0.01
  SLC38A4                                           Solute carrier family 38 member 4                                      0.44          0.02
  MYLK2                                             Myosin light chain kinase 2                                            0.48          0.01
  GOLGA7B                                           Golgin A7 family member B                                              0.48          0.02
  PARP15                                            Poly(ADP-ribose) polymerase family member 15                           0.49          0.04
  TTC39B                                            Tetratricopeptide repeat domain 39B                                    0.50          0.03
  **Lesser known function**                                                                                                              
  UNQ6494                                           Novel transcript                                                       0.25          0.03
  CFAP61                                            Cilia and flagella associated protein 61                               0.38          0.02
  LRRC3B                                            Leucine rich repeat containing 3B                                      0.39          0.04
  FAM184B                                           Family with sequence similarity 184 member B                           0.39          0.02
  AC113133.1                                        Novel transcript, antisense to ANK1                                    0.48          0.02
  ANKRD33B                                          Ankyrin repeat domain 33B                                              0.50          0.02

Fold-change in gene expression post-RT from pre-RT; FDR, false discovery rate.

###### 

Latent variables (LVs) constructed by PLIER.

                Basal comparison   RT intervention                                                
  ------------- ------------------ ----------------- -------------- -------------- -------------- ------------------------------------------------------------------
  LV1^‡^        0.49 ± 0.71        0.13 ± 1.22       −0.24 ± 0.62   −0.20 ± 0.28   −0.89 ± 0.41   REACTOME_GLUCOSE_METABOLISM
  LV2^‡^        0.10 ± 0.94        −0.75 ± 1.09      0.07 ± 0.73    0.32 ± 0.65    1.40 ± 0.50    REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON\_ TRANSPORT
  LV3^‡^        0.39 ± 0.87        −0.29 ± 1.12      −0.28 ± 0.57   −0.27 ± 0.59   0.41 ± 0.70    KEGG_PROTEASOME
  LV4\*^‡^      0.30 ± 0.67        −0.15 ± 0.61      −0.50 ± 0.55   −0.54 ± 0.33   0.84 ± 0.37    N/A
  LV5           0.32 ± 0.60        −0.12 ± 0.69      −0.14 ± 0.89   −0.16 ± 0.8    −0.15 ± 0.84   MIPS_RIBOSOME_CYTOPLASMIC
  LV6^†^        −0.48 ± 0.39       −0.15 ± 0.59      0.46 ± 0.67    0.70 ± 0.31    0.41 ± 0.59    KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION
  LV7           −0.03 ± 0.71       −0.04 ± 0.76      0.21 ± 0.83    0.35 ± 0.75    −0.32 ± 0.34   REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION\_ PATHWAY
  LV8           −0.32 ± 0.88       0.20 ± 0.79       0.11 ± 0.58    0.15 ± 0.52    0.02 ± 0.45    REACTOME_HIV_INFECTION
  LV9           0.31 ± 0.65        −0.17 ± 0.98      0.00 ± 1.24    0.40 ± 1.90    −0.32 ± 1.44   REACTOME_CLASS_I\_MHC_MEDIATED_ANTIGEN\_ PROCESSING_PRESENTATION
  LV10          0.04 ± 0.47        −0.15 ± 0.57      0.11 ± 0.34    0.05 ± 0.31    0.01 ± 0.20    N/A
  LV11          −0.41 ± 0.51       0.15 ± 0.93       0.11 ± 0.72    −0.01 ± 0.78   0.37 ± 0.54    N/A
  LV12          −0.13 ± 0.61       0.12 ± 0.26       −0.03 ± 0.34   0.08 ± 0.36    0.09 ± 0.26    N/A
  LV13^‡^       0.13 ± 0.75        0.35 ± 0.57       0.08 ± 0.56    −0.01 ± 0.51   −1.35 ± 0.27   PID_AR_TF_PATHWAY
  LV14^‡^       −0.22 ± 0.74       0.17 ± 0.34       −0.01 ± 0.34   −0.20 ± 0.12   0.12 ± 0.23    N/A
  LV15          −0.21 ± 0.79       0.30 ± 0.63       −0.17 ± 0.53   −0.37 ± 0.26   0.20 ± 0.40    REACTOME_TRNA_AMINOACYLATION
  LV16\*\*^‡^   −0.38 ± 0.46       0.18 ± 0.36       0.28 ± 0.60    0.34 ± 0.75    −0.21 ± 0.61   N/A
  LV17^‡^       0.10 ± 0.89        −0.11 ± 0.71      −0.20 ± 0.68   −0.12 ± 0.59   0.51 ± 0.33    REACTOME_G\_ALPHA_I\_SIGNALLING_EVENTS
  LV18          0.15 ± 0.60        −0.07 ± 0.41      −0.03 ± 0.64   0.02 ± 0.24    −0.10 ± 0.23   N/A
  LV19          −0.04 ± 0.42       0.20 ± 0.33       0.01 ± 0.52    −0.30 ± 0.58   −0.43 ± 0.72   N/A
  LV20^‡^       0.53 ± 1.93        −0.19 ± 0.57      −0.36 ± 0.49   −0.54 ± 0.28   0.03 ± 0.43    KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
  LV21          −0.16 ± 0.59       0.19 ± 0.34       0.03 ± 0.40    −0.03 ± 0.51   −0.13 ± 0.44   REACTOME_GENERIC_TRANSCRIPTION_PATHWAY
  LV22\*        −0.35 ± 0.69       0.13 ± 0.59       0.33 ± 0.57    0.22 ± 0.78    −0.27 ± 0.36   REACTOME_GENERIC_TRANSCRIPTION_PATHWAY
  LV23^‡^       −0.01 ± 1.08       −0.02 ± 0.59      0.27 ± 0.89    0.68 ± 0.17    −0.56 ± 0.47   KEGG_SPLICEOSOME
  LV24          0.02 ± 0.33        −0.08 ± 0.71      0.13 ± 0.31    −0.02 ± 0.35   −0.17 ± 0.28   N/A
  LV25          −0.11 ± 1.44       0.23 ± 0.77       −0.21 ± 0.72   −0.48 ± 0.63   0.21 ± 0.77    REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION

Values represent mean within each LV (latent variable) ± standard deviation; YA, young adults; OA, older adults; PD, Parkinson's disease; RT, resistance training; N/A, PLIER found no annotation using prior knowledge. \*P \< 0.05 in PD vs. YA;

†

P \< 0.05 in PD vs. both other basal cohorts; \*\*P \< 0.05 in YA vs. both other basal cohorts;

‡

P \< 0.05 between PD pre- and post-RT.

Gene Programs Altered in PD Muscle and Reversed by RT {#S3.SS2}
-----------------------------------------------------

[Table 4](#T4){ref-type="table"} shows 25 LVs identified by PLIER; annotation based on canonical pathways association is provided when available (16 of 25 LVs, 64%) and denoted where not found (N/A). Ten LVs (40%) were significantly different following 16-week RT. Of these, two (LVs 4 and 16) were *both* different at baseline in PD vs. either healthy group *and* significantly reversed following RT. Of the 706 significantly differentially expressed genes in the initial analysis, 38 were in the top 100 of LV4 and 16 were in the top 100 of LV16.

LV4 was significantly lower in PD than YA at baseline (*P* = 0.01) and increased following RT (*P* = 0.004, [Figure 2A](#F2){ref-type="fig"}). Normalized expression of the top 50 transcripts in LV4 is presented in [Figure 2B](#F2){ref-type="fig"}. Since the expression pattern was consistent throughout the top 50 genes, manual annotation was performed for the top 100 genes, revealing prominent associations with neuromuscular adaptations to exercise, including neural development (SPTBN1, DOCK6, and DOCK9), muscle development (PDGFRB and COL5A3), and neuroprotective effects (RASGRF2, AGAP2, and ARRB1), as well as skeletal muscle structural adaptations, such as muscle regeneration (SPARC, NUMB, and NOTCH1), angiogenesis (NRP1, TEK, and ARAP3), and extracellular matrix remodeling (COL4A2, HYAL1, and BMP1). See [Supplementary Data Sheet 3](#FS3){ref-type="supplementary-material"} for full names of the top 100 genes in LV4.

![**(A)** Difference in LV (latent variable) 4 across study groups Basal YA (young adults, *n* = 12), Basal OA (older adults, *n* = 12), Basal PD (Parkinson's disease, *n* = 12), and PD post-RT (rehabilitation training, *n* = 5). Individual points are shown for each subject, and lines represent the change within the five individuals with PD that underwent RT. Among the basal groups, LV4 was significantly lower in PD vs. YA (*P* = 0.009) and increased following RT (*P* = 0.004). **(B)** Heatmap showing normalized expression of the top 50 genes in LV4, illustrating expression profile across study groups. Full gene names are available in [Supplementary Data Sheet 3](#FS3){ref-type="supplementary-material"}.](fphys-11-00653-g002){#F2}

Conversely, LV16 was significantly elevated in PD (*P* = 0.004) and OA (*P* = 0.007) vs. YA at baseline, suggesting a primary effect of age ([Figure 3A](#F3){ref-type="fig"}); RT significantly reduced LV16 (*P* = 0.008). Normalized expression of the top 50 genes in LV16 is presented in [Figure 3B](#F3){ref-type="fig"}. Functional annotation of the top 100 genes in LV16 revealed involvement in age-related muscle dysfunction, e.g., denervation (NCAM, SCN5A, PLEKHB1, and ERBB3), autophagy (DRAM1, RAB23, and TECPR2), apoptosis (DNAJB4, SEC61A1, and GBP2), and inflammation/immunity (TLE4, PDE71, and DUSP10). [Supplementary Data Sheet 4](#FS4){ref-type="supplementary-material"} provides full names for the top 100 transcripts in LV16.

![**(A)** Difference in LV (latent variable) 16 across study groups Basal YA (young adults, *n* = 12), Basal OA (older adults, *n* = 12), Basal PD (Parkinson's disease, *n* = 12), and PD post-RT (rehabilitation training, *n* = 5). Individual points are shown for each subject, and lines represent the change within the five individuals with PD that underwent RT. Among the basal groups, expression of LV16 was significantly higher in both PD (*P* = 0.005) and OA (*P* = 0.019) vs. YA. Expression was reduced following RT (*P* = 0.008). **(B)** Heatmap showing normalized expression of the top 50 genes in LV16, illustrating expression profile across study groups. Full gene names are available in [Supplementary Data Sheet 4](#FS4){ref-type="supplementary-material"}.](fphys-11-00653-g003){#F3}

Discussion {#S4}
==========

This study marks the discovery of two transcriptional programs altered in skeletal muscle by the presence of PD and/or aging and rescued by intensive resistance exercise training. Using the innovative PLIER algorithm to complement a standard differential gene expression workflow, we have revealed coordinated transcriptomic patterns in skeletal muscle associated with PD at baseline and in response to RT. Literature-based interrogation of these transcripts highlights their associations with physiological processes of potential relevance to PD symptomology. In particular, we detected heightened expression of genes associated with muscle regeneration and neural development, and reduced expression of genes associated with apoptosis, autophagy, and immunity. These results provide a potential mechanistic basis for RT-induced improvements in motor and non-motor PD symptoms and direction for future investigations into the impact of intensive exercise rehabilitation on aging and neurodegenerative disease.

Genes Linked to Exercise-Induced Neuromuscular Adaptations {#S4.SS1}
----------------------------------------------------------

Utilizing the PLIER framework, we were able to expand greatly upon the single gene-level findings. The finding that a large fraction (16--38%) of the top 100 genes in the LVs of interest were significantly different at the single-transcript level provides a validation of our approach, while further highlighting the utility of network-based analyses to illuminate new relationships among gene sets. At the single-transcript level, we observed patterns that make intuitive sense following RT, such as an increase in expression of genes associated with muscle development and extracellular matrix remodeling \[e.g., IGFN (immunoglobulin-like and fibronectin type III domain-containing)1 and a cluster of collagenase enzymes\] ([@B22]; [@B38]) and a decrease in factors that inhibit muscle growth \[e.g., MSTN (myostatin), neuronal pentraxin (NPTX)1\] ([@B71]; [@B58]; [@B21]). Similarities with existing data sets in healthy humans illustrates the important point that skeletal muscle of individuals with PD is responsive to exercise, despite the prominent peripheral manifestation of the disease. Changes in myosin heavy chain isoform expression support our histological evidence of partial type I myofiber grouping reversal with RT ([@B25]): we observed decreased expression of in MYH (myosin heavy chain)1, MYLK (light-chain kinase)2, and others involved in aerobic metabolism, such as PRKAG (protein kinase AMP-activated non-catalytic subunit gamma)3 ([@B17]). Application of PLIER allowed us to link other genes to these, amplifying our ability to understand pathways and processes impacted by RT in the PD population.

We previously demonstrated that heightened expression of transcripts involved in neural development was associated with type I grouping in PD skeletal muscle ([@B33]), believed to be a result of denervation-reinnervation processes accelerated in PD ([@B37]; [@B25]). Presently, we detected reversal in direction of expression of a handful of these genes with RT, including transcription factors NFAT (nuclear factor of activated T-cells)5 and ZNF (zinc finger proteins) 689 and 24, the latter of which enables cell cycle progression in early neural development ([@B28]). Because our small sample size did not mirror the reversal of type I grouping seen in the larger cohort ([@B25]), these findings provide only preliminary insight into the mechanism of type I grouping reversal with exercise. Nevertheless, several genes related to neural development were upregulated as a result of RT, further supporting that neuromuscular communication and likely physical contact may be altered as a result of PD and modulated by exercise. This was a feature of LV4, wherein a number of genes have been linked to in neurite outgrowth, \[e.g., SPTBN1 (spectrin beta 1) and DOCK (dedicators of cytokinesis) 6 and 9 ([@B47]; [@B32]; [@B34])\], neural patterning \[e.g., MLLT (myeloid/lymphoid or mixed-lineage leukemia; translocated to)4, TSPAN (tetraspanin)18 ([@B10]; [@B62])\], and axon guidance \[e.g., NRP (neuropilin)1, PLXN (plexin)D1, SEMA (semaphorin)5A ([@B20]; [@B50]; [@B30])\]. Larger studies in the future are necessary to determine whether the gene networks we previously identified as correlates of myofiber grouping are impacted during an RT regimen that partially reverses type I grouping or a completely different gene set is involved.

Genes Linked to Dynamics of Denervation and Neural Apoptosis {#S4.SS2}
------------------------------------------------------------

Along with a noted increase in expression of genes related to neural functioning and development, RT promoted decreased expression of genes often overexpressed in denervated skeletal muscle. Both SCN5A (voltage-gated sodium channel 5A, known also as Na~v~1.5) and NCAM (neural cell adhesion molecule) were among the top 50 genes grouped into LV16. These factors are often assessed as markers of denervation in adult skeletal muscle ([@B59]; [@B64]; [@B18]; [@B67]). The reduction in expression of these transcripts following RT supports our laboratory's previous findings ([@B25]) and provides direction toward other possible targets for assessment in muscle denervation-reinnervation cycling, including ERBB3 (Erb-B2 receptor tyrosine kinase 3) ([@B48]) and MAGED1 (melanoma antigen gene family D1) ([@B41]).

Like these denervation markers, expression of genes linked to neural apoptosis was increased with aging and reduced with exercise. Of interest, DNAJ (heat shock family member)B4 enhances apoptosis in neural ([@B35]) and other ([@B40]) tissue, while GBP (guanylate binding protein)2 is involved in caspase signaling to promote cell death in neurons ([@B46]). Additionally, RT reduced expression of SMURF (SMAD-specific E3 ubiquitin ligase)1, which is associated with neuroinflammation and necroptosis ([@B65]) linking its function to a potential role in neurodegenerative diseases. Conversely, we noted an increase in expression of SCT (secretin), which is reported to cross the blood--brain barrier and may exert neuroprotective effects ([@B9]; [@B43]; [@B75]). Expression of other neuroprotective genes was upregulated by exercise, including ARRB (arrestin beta)1 ([@B76]) and AGAP (ArfGAP with GTP-ase domain, ankyrin repeat and pH domain)2. In animals, AGAP2 is sequestered by α-synuclein, a hallmark of PD pathology in other tissues ([@B2]) leading to death of dopaminergic neurons ([@B23]). The present findings may suggest that exercise-trained muscle can play an active compensatory role in this balance of neural death and survival in favor of neuroprotection in aging humans. Despite the sample size limitation, the current findings using the novel data integration platform PLIER are nonetheless remarkable and provide a strong basis for future study in larger cohorts.

Genes Linked to PD Pathology {#S4.SS3}
----------------------------

The skeletal muscle gene signature may provide valuable insight into PD severity, and the plasticity of muscle in response to exercise training may represent an ideal intervention for symptom reversal. ZNF160, recently reported to be a negative circulating biomarker of PD \[higher expression associated with a better score on UPDRS, ([@B63])\] was elevated by exercise. Expression of genes linked to abnormal brain and/or neuronal phenotypes in animal models of PD was downregulated by exercise. These include aquaporin (AQP)9 ([@B68]), microtubule affinity regulating kinase (MARK)2, and others associated with aggregation of pathological proteins in neurodegenerative conditions \[e.g., RANBP (RAN binding protein)10 and ABCA (ATP-binding cassette subfamily A)5 ([@B29]; [@B19])\]. Like AGAP2 above, SPTBN1 promotes neuronal differentiation but is inhibited by α-synuclein ([@B34]). Its upregulation at the transcript level in muscle following RT supports a potential compensatory role for skeletal muscle that is enhanced by exercise training. We also detected an increase in FYN (Fyn proto-oncogene), which interacts in microglia with tau ([@B49]) a neurofibrillary protein commonly dysregulated in PD ([@B36]). As this could have potential therapeutic implications, it is necessary to investigate whether skeletal muscle communicates with other relevant tissues, potentially by packaging and releasing factors (e.g., into exosome-like vesicles) that directly interact with α-synuclein and other proteins pathologically altered in PD in order to modulate their impact on functioning. Future research is necessary to determine the communicative role of skeletal muscle in PD before and after an exercise regimen.

Finally, RT induced gene expression of both SIPA1L (signal-induced proliferation associated 1 like)2 and LOXHD (lipoxygenase homology domains)1, genomic variants in which are associated with PD in previous studies ([@B61]; [@B74]; [@B13]; [@B70]). Presently, there is no available evidence of single-nucleotide polymorphisms in these genes contributing to differential expression in healthy skeletal muscle tissue. Thus, further studies integrating genomic and transcriptomic data are needed in order to elucidate whether increased expression of PD-linked genes with RT represents a direct action of exercise to compensate for PD-associated symptoms at the systemic level. In further support, RASGRF (Ras protein specific guanine nucleotide releasing factor)2, upregulated by RT, is associated with synaptic plasticity ([@B11]) and VIPR (vasoactive intestinal peptide receptor)1 may alleviate constipation in PD ([@B15]) a distressing non-motor symptom affecting many individuals with PD ([@B52]).

Study Limitations {#S4.SS4}
-----------------

The absence of a control group (e.g., PD cohort remaining sedentary for 16 weeks, or healthy cohort performing RT) is a limitation of this study. We aimed to eliminate the potential influence of this by focusing our attention on LVs that not only changed with RT but changed in the direction of the healthy groups. For example, LV16 was more highly expressed in both older groups (PD and OA) than in young adults, suggesting a primary effect of aging. While many transcripts in this LV were relevant to PD pathologies, future work with a larger sample size is necessary to determine whether these factors are more highly expressed in PD than in OA skeletal muscle at the gene or protein level. Further, our findings are limited to the individuals studied (Hoehn and Yahr stages 2 and 3, mainly male, older adults). Certainly, a larger study sample size would enable detection of smaller fold-changes pre- to post-RT, including a greater number of genes in downstream functional annotation. However, our approach using PLIER allowed us to detect relationships among transcripts differentially expressed at the single gene-level and others that did not reach significance.

Several transcripts of interest identified in this study do not yet have a known biological role (at the protein level) in skeletal muscle. Rather than a limitation, we consider this a benefit of a discovery project, perhaps catalyzing future research. Finally, the skeletal muscle biopsy samples sequenced in this study represent a heterogenous tissue that includes other cell types ([@B16]; [@B60]) meaning that neuronal, glial, or other cell types may have contributed to our detection of neuroactive factors such as SPTBN1 and GBP2. Nevertheless, myofibers make up the vast preponderance of the muscle biopsy specimen; thus, it is most likely that transcripts identified here primarily reflect the transcriptional profile of muscle tissue. The fact that most available evidence regarding the biological roles of these transcripts is drawn from neural cells/tissue highlights the present knowledge gap in potential peripheral roles of these factors in PD. Future work is needed in order to assess whether these transcripts are translated in isolated muscle cells, and subsequently whether they act in an autocrine/paracrine fashion, are degraded, or may be packaged into extracellular vesicles by skeletal muscle.

Conclusion {#S5}
==========

This study is the first to examine skeletal muscle gene expression in individuals with Parkinson's disease following exercise rehabilitation training. In doing so, we identified a robust effect of training, with 706 genes differentially expressed after RT. Application of the PLIER algorithm identified two gene programs that are altered by PD and rescued by RT. The present findings, in combination with our previous work ([@B25]; [@B33]) strengthen our understanding of skeletal muscle as a communicative tissue in exercise, aging, and neurodegenerative disease. Further, findings support that, by optimizing muscle health throughout an exercise training regimen, therapeutic effects seen in other tissues and systems may have a mechanistic basis in alterations at the level of the skeletal muscle transcriptome. Future investigations are necessary to determine the influence of exercise training on other levels of phenotype in PD and how skeletal muscle may reflect or orchestrate these changes.
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